New Research Links Insulin Dosing, SGLT Inhibitors, and Amputation Risks to Heart Trouble in Diabetes

Key takeaways

• Larger insulin bolus doses are tied to more heart‑sympathetic activity during sleep, even when blood sugar levels stay the same [2].
• Experts note that SGLT‑inhibitor drugs could protect the heart and kidneys in type 1 diabetes, but trials must use safe designs and watch for diabetic ketoacidosis (DKA) [3].
• One‑year death after a below‑knee amputation is 23.5 %; it climbs to 82.3 % after ten years, with older age, female sex, and more health problems increasing risk [1].
• Heart attacks occur in 3.74 % of patients within 90 days after below‑knee amputation, highlighting a link between limb loss and cardiac events [1].

Insulin Doses May Shift the Heart’s Balance

A free‑living study examined adults with type 1 diabetes who used insulin pumps or injections [2]. Researchers measured cardiac autonomic balance—how the nervous system controls the heart—while participants went about daily life [2]. They found that a higher last bolus insulin dose (the final rapid‑acting shot before bedtime) was linked to cardiac sympathetic predominance during the early part of sleep [2]. Higher basal insulin doses (the steady background insulin) were associated with sympathetic dominance during the late sleep phase [2]. These links held even after accounting for blood‑sugar readings, indicating the effect was independent of glycemic control [2]. The authors note that the study does not prove that insulin causes heart problems [2].

SGLT Inhibitors: Promise and Peril for Type 1 Diabetes

The expert panel notes that early data suggest SGLT inhibitors could reduce the burden of heart and kidney disease in type 1 diabetes [3]. The evidence base is still thin, and traditional large‑scale trials that look for hard outcomes are difficult to power in the smaller type 1 population [3]. The panel proposes using surrogate end points (such as changes in albuminuria) to make trials more feasible [3]. A major safety concern is diabetic ketoacidosis (DKA), and the experts stress that any trial must collect detailed DKA data and apply strict risk‑mitigation protocols [3]. While such protocols exist, the panel admits that rigorous data proving they work are still lacking [3].

Alarming Mortality After Below‑Knee Amputation

A 25‑year English population study tracked 25,176 people with diabetes who underwent a below‑knee amputation (BKA), the most common major amputation for advanced diabetic foot disease [1]. One‑year mortality after BKA was 23.5 %, and mortality rose to 82.3 % by ten years [1]. The study identified three factors that increased death risk: older age, female sex, and a higher Charlson Comorbidity Index [1]. Each point increase in this index raised the death hazard by 1.04 times, while being female added a hazard ratio of 1.06, and older age added 1.62 [1]. Complications within the first 90 days were common: reoperation occurred in 6.24 %, myocardial infarction in 3.74 %, and readmission for any cause in 20.25 % of patients [1]. Contralateral amputation happened in 6.43 % of survivors over five years [1]. These figures have not improved since 2012 [1].